Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review.

Abstract

Although testosterone replacement therapy is an effective treatment for hypogonadism, there are safety concerns regarding potential cardiovascular risks and fertility preservation. To assess the effect of selective estrogen receptor modulator (SERM), aromatase inhibitor, and human chorionic gonadotropin (hCG) on total testosterone (TT) levels and hypogonadism. We performed a systematic literature review from 1987 to 2019 via PubMed, Cochrane review, and Web of Science. Terms used were infertility, hypogonadism, alternative to testosterone therapy, selective estrogen receptor modulator, aromatase inhibitor, and human chorionic gonadotropin. Studies that reported an effect of TT and hypogonadism after treatment of each medication were selected. Hypogonadal symptoms were assessed by the Androgen Deficiency of The Aging Male (ADAM) questionnaire. Aggregated data were analyzed via Chi-squared analysis. From literature, 25 studies were selected; of which, 12 evaluated efficacy of aromatase inhibitor, 8 evaluated SERMs, and 5 evaluated hCG effects. For SERMs, 512 patients with mean age 42.3±1.94years showed mean TT before treatment vs after treatment (167.9±202.8 [ng/dl] vs 366.2±32.3 [ng/dl], P<.0001 [180.5-216.1 95% confidence interval {CI}]). For aromatase inhibitor, 375 patients with mean age 54.1±0.67years showed mean TT before treatment vs after treatment (167.9±202.8 [ng/dl] vs 366.2±32.3 [ng/dl], P<.0001 [180.5-216.1 95% CI]). SERMs also showed ADAM before treatment vs after treatment (4.95±0.28 vs 5.50±0.19, P<.0001 [0.523-0.581 95% CI]). For hCG, 196 patients with mean age 41.7±1.5years showed mean TT before treatment vs after treatment (284.5±13.6 [ng/dl] vs 565.6±39.7 [ng/dl], P<.0001 [275.2-287.0 95% CI]). In addition, hCG also showed ADAM before treatment vs after treatment (28.1±2.0 vs 30.9±2.3, P<.0001 [2.313 95% CI]). Non-testosterone therapies are efficacious in hypogonadal men. Our results show statistically significant improvement in TT and ADAM scores in all 3 medications after treatment. Future studies are warranted to elucidate the relationship between improved hypogonadism and erectile function in the setting of non-testosterone-based treatment. Raheem OA, Chen TT, Le TV, etal. Efficacy of Non-Testosterone-Based Treatment in Hypogonadal Men: A Review. Sex Med Rev 2021;9:381-392.